CRRT联合PE治疗慢加急性乙型肝炎肝衰竭并发急性肾损伤患者疗效研究*

doi:10.3969/j.issn.1672-5069.2020.06.019

摘要/Abstract

摘要： 目的研究采用持续性肾脏替代治疗(CRRT)联合血浆置换(PE)治疗慢加急性乙型肝炎肝衰竭并发急性肾损伤(AKI)患者的临床疗效。方法 2016年10月~2019年11月于我院重症医学科救治的65例慢加急性乙型肝炎肝衰竭并发AKI患者,其中35例接受CRRT联合PE治疗,30例接受PE治疗。计算估算的肾小球滤过率(eGFR)、肌酐清除率(Ccr)和联合钠的终末期肝病模型(MELD-Na)。结果联合组患者90 d生存率为54.3%,显著高于PE组的23.3%(P<0.05);在治疗后90 d,联合组19例生产者血清总胆红素水平为(28.8±11.1)μmol/L,显著低于PE治疗组7例生存者的【(39.4±13.0)μmol/L,P<0.05】;在治疗后28 d,联合组25例生存者eGFR水平为(79.4±24.7) mL/min/1.73 m²,显著高于PE组16例生存者的【(65.75±16.1)mL/min/1.73 m²,P<0.05】,Ccr水平为(77.3±25.7)mL/min,显著高于PE组的【(63.4±20.1)mL/min,P<0.05】,MELD-Na水平为(22.4±4.5)分,显著低于PE组的【(29.5±4.1)%,P<0.05】,在治疗90 d,两组上述指标差异无统计学意义(P>0.05)。结论联合采用CRRT和PE治疗慢加急性乙型肝炎肝衰竭并发AKI患者可提示短期生存率,可能与保护肝肾功能有关,值得临床进一步研究。

关键词: 慢加急性肝衰竭, 乙型肝炎, 急性肾损伤, 持续性肾脏替代治疗, 血浆置换, 治疗

Abstract: Objective The purpose of this study was to investigate the efficacy of continuous renal replacement therapy (CRRT) and plasma exchange (PE) combination in the treatment of patients with acute-on-chronic hepatitis B liver failure (ACLF) complicated by acute kidney injury (AKI). Methods 65 ACLF patients caused by hepatitis B viral infection and AKI were treated in ICU of our hospital between October 2016 and November 2019, and 35 cases received CRRT and PE combination and 30 received PE alone at base of conventional supporting management. The estimated glomerular filtration rate (eGFR), creatinine clearance rate (Ccr) and model for end-stage liver disease-Na (MELD-Na) were calculated. Results The survival rate in combination-treated group at day 90 was 54.3%, significantly higher than 23.3% in the PE-treated group (P<0.05); at the end of 90 day treatment, serum bilirubin level in 19 survivals in CRRT and PE-treated group was (28.8±11.1) μmol/L, much lower than 【(39.4±13.0) μmol/L, P<0.05】 in 7 patients in PE-treated group; at the end of day 28, the eGFR in 25 survivals in CRRT and PE combination-treated group was (79.4±24.7) mL/min/1.73 m², significantly higher than (65.75±16.1)mL/min/1.73 m², P<0.05】, the Ccr was (77.3±25.7)mL/min, much higher than 【(63.4±20.1)mL/min, P<0.05】, and the MELD-Na score was (22.4±4.5), significantly lower than 【(29.5±4.1)%, P<0.05】 in 16 survivals in PE-treated group, while the three parameters above mentioned in the survivals of the two groups at day 90 were not significantly different (P>0.05). Conclusion The application of CRRT and PE in the treatment of patients with ACLF caused byhepatitis B viral infection and complicated by AKI could reduce the short-term mortality, which might protect the liver and kidney functions and warrants further multi-central clinical trials.

Key words: Acute-on-chronic liver failure, Hepatitis B, Acute kidney injury, Continuous renal replacement therapy, Plasma exchange, Therapy

关万涛, 康福新, 林维, 林宏云, 黎仕焕. CRRT联合PE治疗慢加急性乙型肝炎肝衰竭并发急性肾损伤患者疗效研究^*[J]. 实用肝脏病杂志, 2020, 23(6): 833-836.

Guan Wantao, Kang Fuxin, Lin Wei, et al. Decreased 90-day mortality in patients with hepatitis B-induced acute-on-chronic liver failure and acute kidney injury by continuous renal replacement therapy and plasma exchange treatment[J]. Journal of Practical Hepatology, 2020, 23(6): 833-836.

参考文献

[1] Singal AK, Ong S, Satapathy SK, et al. Simultaneous liver kidney transplantation. Transpl Int, 2019, 32(4): 343–352.
[2] MacDonald AJ, Nadim MK, Durand F, et al. Acute kidney injury in cirrhosis: implications for liver transplantation. Curr Opin Crit Care, 2019, 25(2): 171–178.
[3] 王媛, 党盼玉, 王伟. 血浆置换联合连续性血浆透析滤过治疗慢加急性肝衰竭患者临床疗效及其对血浆细胞因子水平的影响. 实用肝脏病杂志, 2019, 22(4): 541-544.
[4] Coelho S, Fonseca JN, Gameiro J, et al. Transient and persistent acute kidney injury in acute liver failure. J Nephrol, 2019, 32(2): 289–296.
[5] 中华医学会感染病学分会肝衰竭与人工肝学组, 中华医学会肝病学分会重型肝病与人工肝学组. 肝衰竭诊治指南(2018年版). 实用肝脏病杂志, 2019, 22(2): 164-171.
[6] Ugamura A, Chu PS, Nakamoto N, et al. Liver fibrosis markers improve prediction of outcome in non-acetaminophen-associated acute liver failure. Hepatol Commun, 2018, 2(11):1331-1343.
[7] Arora V, Maiwall R, Rajan V, et al. Terlipressin is superior to noradrenaline in the management of acute kidney injury in acute on chronic liver failure. Hepatology, 2020, 71(2): 600–610.
[8] Lin S, Zhang DD, Gao Y, et al. Letter to editor: the synergistic effect of albumin on terlipressin in acute-on-chronic liver failure with acute kidney injury. Hepatology, 2019, 69(4): 1845.
[9] Wajda J, Dumnicka P, Maraj M, et al. Potential prognostic markers of acute kidney injury in the early phase of acute pancreatitis. Int J Mol Sci, 2019, 20(15): 3714.
[10] Sarin SK, Choudhury A, Sharma MK, et al. Acute-on-chronic liver failure: consensus recommendations of the Asian Pacific association for the study of the liver (APASL): an update. Hepatol Int, 2019, 13(4): 353–390.
[11] Mallakmir S, Nagral A, Bagde A, et al. Mutation in the neuroblastoma amplified sequence gene as a cause of recurrent acute liver failure, acute kidney injury, and status epilepticus. J Clin Exp Hepatol, 2019, 9(6): 753–756.
[12] 马德渊, 马元凤, 张殿隆, 等. HBV相关慢加急性肝衰竭患者血清角蛋白18水平及其与患者预后的关系探讨. 实用肝脏病杂志, 2019, 22(1): 77-80.
[13] Thongprayoon C, Kaewput W, Thamcharoen N, et al. Incidence and impact of acute kidney injury after liver transplantation: a meta-analysis. J Clin Med, 2019, 8(3): 372.
[14] Griffin BR, Jovanovich A, You Z, et al. Effects of baseline thrombocytopenia and platelet decrease following renal replacement therapy initiation in patients with severe acute kidney injury. Crit Care Med, 2019, 47(4): e325–e331.
[15] Woodward CW, Lambert J, Ortiz-Soriano V, et al. Fluid overload associates with major adverse kidney events in critically ill patients with acute kidney injury requiring continuous renal replacement therapy. Crit Care Med, 2019, 47(9): e753–e760.
[16] Murugan R, Kerti SJ, Chang CH, et al. Association of net ultrafiltration rate with mortality among critically ill adults with acute kidney injury receiving continuous venovenous hemodiafiltration: a secondary analysis of the randomized evaluation of normal vs augmented level (renal) of renal replacement therapy trial. JAMA Netw Open, 2019, 2(6): e195418.
[17] Alvarez G, Chrusch C, Hulme T, et al. Renal replacement therapy: a practical update. traitement substitutif de l'insuffisance rénale : une mise à jour pratique. Can J Anaesth, 2019, 66(5): 593–604.
[18] Nand N, Verma P, Jain D. Comparative evaluation of continuous veno-venous hemodiafiltration and continuous arterio-venous hemodiafiltration in patients of hepatic failure and / or hepatorenal syndrome. J Assoc Physicians India, 2019, 67(8): 39–42.
[19] Wan YM, Li YH, Xu ZY, et al. Genotype matters in patients with acute-on-chronic liver failure due to reactivation of chronic hepatitis B. Clin Transl Gastroenterol, 2018,9(11):202.
[20] Niewinski G, Raszeja-Wyszomirska J, Hrenczuk M, et al. Intermittent high-flux albumin dialysis with continuous venovenous hemodialysis for acute-on-chronic liver failure and acute kidney injury. Artif Organs, 2020, 44(1): 91–99.

CRRT联合PE治疗慢加急性乙型肝炎肝衰竭并发急性肾损伤患者疗效研究^*

Decreased 90-day mortality in patients with hepatitis B-induced acute-on-chronic liver failure and acute kidney injury by continuous renal replacement therapy and plasma exchange treatment

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	周新民, 丁小鹏. 基础肝病治疗在原发性肝癌综合治疗中的重要作用[J]. 实用肝脏病杂志, 2021, 24(1): 4-6.
[2]	刘奇, 郝吉庆. 免疫联合治疗肝细胞癌研究进展[J]. 实用肝脏病杂志, 2021, 24(1): 7-9.
[3]	郑志恒, 李维筠, 回振宇, 陈莹. 聚乙二醇干扰素α-2a联合恩替卡韦治疗慢性乙型肝炎患者疗效及血清Pygo2和GP73水平变化[J]. 实用肝脏病杂志, 2021, 24(1): 19-22.
[4]	吴冬秋, 崔丽华, 熊峰, 邬政宏. 血清IL-34联合超声弹性成像诊断慢性乙型肝炎患者肝纤维化的效能分析[J]. 实用肝脏病杂志, 2021, 24(1): 23-26.
[5]	林金祥, 杨可立. PEG-IFNα-2a与PEG-IFNα-2b治疗慢性乙型肝炎患者疗效研究[J]. 实用肝脏病杂志, 2021, 24(1): 27-30.
[6]	樊秉栋, 张国华, 王君. 索磷布韦/维帕他韦联合利巴韦林治疗慢性丙型肝炎患者疗效临床研究[J]. 实用肝脏病杂志, 2021, 24(1): 31-34.
[7]	杨晓冬, 贾婷, 张秀灵, 高斯媛, 余向琼, 李冬玲, 喻明丽, 林潮双. 达诺瑞韦联合长效α-干扰素治疗基因3型慢性丙型肝炎患者疗效研究[J]. 实用肝脏病杂志, 2021, 24(1): 35-38.
[8]	魏秀琴, 闫晓霞, 石国荣, 赵宏伟, 李基寿. 阿托伐他汀联合硫普罗宁治疗非酒精性脂肪性肝病患者疗效初步研究[J]. 实用肝脏病杂志, 2021, 24(1): 47-50.
[9]	李钊, 黄赞松, 李繁. 非诺贝特联合双环醇治疗非酒精性脂肪性肝病患者肝组织PPARγ₂mRNA水平变化[J]. 实用肝脏病杂志, 2021, 24(1): 59-62.
[10]	陈金玉, 郭晓霞, 钟晓妮. 二甲双胍联合双歧杆菌三联活菌胶囊治疗非酒精性脂肪性肝病患者疗效及血清IRS1、IRS2和GLUT4的变化[J]. 实用肝脏病杂志, 2021, 24(1): 63-66.
[11]	陈燕屏, 黄绍强, 邓鑫, 熊超. 硫普罗宁联合多烯磷脂酰胆碱治疗酒精性肝病患者疗效及血清TLR4、MD-2和TGF-β1水平变化[J]. 实用肝脏病杂志, 2021, 24(1): 67-70.
[12]	蔡宇, 王孟春, 邱新平, 张宁宁, 刘丽莉, 吴博, 杨奇. 复方甘草酸苷联合丁二磺酸腺苷蛋氨酸治疗酒精性肝炎伴胆汁淤积患者疗效研究[J]. 实用肝脏病杂志, 2021, 24(1): 71-74.
[13]	伍畅, 田园, 刘洪岩. 酪酸梭菌活菌辅助硫普罗宁和美他多辛治疗酒精性肝病患者疗效及其对患者肠道菌群分布的影响[J]. 实用肝脏病杂志, 2021, 24(1): 75-78.
[14]	李庆玲, 何树光, 易小明, 段婷娜, 周意. 雷公藤多甙联合异甘草酸镁治疗自身免疫性肝炎患者外周血淋巴细胞PD-1和PD-L1变化[J]. 实用肝脏病杂志, 2021, 24(1): 79-82.
[15]	宋金云, 王建芳, 赵宏宇. 慢性乙型肝炎和肝硬化患者血清HBV基因型分析[J]. 实用肝脏病杂志, 2021, 24(1): 87-90.